Your browser doesn't support javascript.
loading
GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease.
Zhang, Arianna J; Perez-Chada, Lourdes M; Strand, Vibeke; Armstrong, April W; Gottlieb, Alice B; Merola, Joseph F.
Affiliation
  • Zhang AJ; A.J. Zhang, BA, Department of Dermatology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
  • Perez-Chada LM; L. Perez-Chada, MD, MMSc, Department of Dermatology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
  • Strand V; V. Strand, MD, Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California.
  • Armstrong AW; A.W. Armstrong, MD, MPH, Division of Dermatology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Gottlieb AB; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Merola JF; J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA.
J Rheumatol ; 2024 Jul 15.
Article in En | MEDLINE | ID: mdl-39009404
ABSTRACT
During the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the International Dermatology Outcome Measures (IDEOM) psoriatic disease (PsD) workgroup presented an update on their efforts toward measurement of musculoskeletal (MSK) symptoms in patients with PsD. Dr. Joseph Merola initiated the presentation emphasizing the vital importance of assessing MSK symptoms in patients with psoriasis (PsO) regardless of whether they have been diagnosed with psoriatic arthritis (PsA). He also discussed existing challenges for evaluating MSK symptoms in patients with PsO without a PsA diagnosis. Dr. Lourdes Perez-Chada then presented their work on the development and validation of the IDEOM Musculoskeletal Questionnaire (MSK-Q), a patient-reported questionnaire developed by the IDEOM to capture the intensity and impact of MSK symptoms on quality of life in patients with PsO with or without PsA. Dr. Perez-Chada also introduced a set of ongoing studies employing the IDEOM MSK-Q, highlighting the potential effects of the data collected through this innovative tool.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Rheumatol Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Rheumatol Year: 2024 Document type: Article